ASPEN PHARMACARE HOLDINGS LIMITED - Aspen concludes agreement to manufacture and make available an Aspen-branded Covid-19 vaccine (Aspenovax)

Aspen concludes agreement to manufacture and make available an Aspen-branded Covid-19 vaccine (Aspenovax)

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)



ASPEN CONCLUDES AGREEMENT TO MANUFACTURE AND MAKE AVAILABLE AN ASPEN-BRANDED COVID-
19 VACCINE (ASPENOVAX) THROUGHOUT AFRICA

Shareholders are referred to the announcement of 30 November 2021 wherein it was confirmed that the
Group had been in discussions to conclude an agreement to manufacture and make available an Aspen-
branded COVID-19 vaccine. Aspen Holdings is now pleased to confirm that one of its wholly-owned South
African subsidiaries, Aspen SA Operations (Pty) Limited (“Aspen SA Operations”), has concluded an
agreement (“Agreement”) with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical
Companies of Johnson & Johnson (“Johnson & Johnson”, together “the Parties”), to manufacture and make
available an Aspen-branded COVID-19 vaccine, “Aspenovax”(1), throughout Africa.

The terms of the Agreement expand the existing technical transfer and manufacturing agreements
between the Parties to grant Aspen SA Operations the rights to:
 (i)  manufacture finished Aspenovax product from drug substance supplied by Johnson & Johnson; and
 (ii) make available Aspenovax to markets in Africa through transactions with designated multilateral
      organisations and with national governments of member states of the African Union.

Under the Agreement, Aspen has secured the enabling intellectual property from Johnson & Johnson and
there is a good faith undertaking between the Parties to discuss the expansion of the Agreement to include
any new versions of the drug substance, such as those developed for new variants or a different
formulation for administration as a booster, and the applicable terms thereof.

The Agreement endures until 31 December 2026.


Footnote:
(1) Aspen SA Operations has undertaken the required process to assess the acceptability of the Aspenovax name with
    the South African Health Products Regulatory Authority.


Durban
08 March 2022

Sponsor
Investec Bank Limited



Date: 08-03-2022 05:20:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.